Targeting STAT3 in Cancer Immunotherapy.

Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. · 2020

Read Targeting STAT3 in Cancer Immunotherapy. by Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7513516.txt.

Introduction

Zou and co-authors review STAT3 as a target in cancer immunotherapy. STAT3 is a signal protein where many cancer pathways converge. It is overactive in tumor cells and in other cells of the tumor setting.

Active STAT3 blocks genes that switch on immune attack. It also boosts factors that suppress the immune response. That double role helps tumors hide from the body's defenses. Blocking STAT3 has thus become a promising plan for many cancers. The review sets out STAT3's part in tumor growth and immune control. It surveys drugs in development that aim at the pathway. Pairing STAT3 blockers with other immunotherapies gets close attention. The authors see such pairs as a route to stronger cancer treatments.

Catalog record

CREATORZou S, Tong Q, Liu B, Huang W, Tian Y, Fu X.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE88 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7513516

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Targeting STAT3 in Cancer Immunotherapy By Sailan Zou, Qiyu Tong, Bowen Liu, Wei Huang, Yan Tian, Xianghui Fu Published in: Molecular Cancer DOI: 10.1186/s12943-020-01258-7 ABSTRACT As a point of convergence for numerous oncogenic signaling pathways, signal transducer and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune response. STAT3 is broadly hyperactivated both in cancer and non-cancerous cells within the tumor ecosystem and plays important roles in inhibiting the expression of crucial immune activation regulators and promoting the production of immunosuppressive factors. Therefore, targeting the STAT3 signaling pathway has emerged as a promising therapeutic strategy for numerous cancers. In this review, we outline the importance of STAT3 signaling pathway in tumorigenesis and its immune regulation, and highlight the current status for the development of STAT3-targeting therapeutic approaches. We also summarize and discuss recent advances in STAT3-based combination immunotherapy in detail. These endeavors provide new insights into the translational application of STAT3 in cancer and may contribute to the promotion of more effective treatments toward malignancies. INTRODUCTION Dysregulation of immune checkpoints is a protective mechanism used by a number of malignancies to escape from the immune surveillance allowing for cancer development [1]. This has inspired the idea of boosting the host immune response as an anti-cancer therapy. Indeed, the blockage of immune checkpoints, including programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), improves clinical outcomes in subsets of patients with cancers previously considered to be essentially untreatable [2–4]. In order to expand the array of treatable cancers as well as increase the number of patients that respond to the therapy, novel therapeutic targets and new molecules/strategies should be urgently identified and developed for immunotherapy appropriate for the clinical use. The signal transducer and activator of transcription (STAT) proteins are a family of cytoplasmic transcription factors which share an overall general structure, organized into functional modular domains. The mammalian STAT family comprises STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 that mediate multiple intracellular signaling pathways [5]. Among them, STAT3 is involved in numerous biological processes including cell proliferation, survival, differentiation, and angiogenesis [6, 7]. In normal cells, transient activation of STAT3 (predominantly by phosphorylation) transmits transcriptional signals from cytokines and growth factor receptors at the plasma membrane to the nucleus [5]. In contrast, STAT3 becomes hyperactivated in the majority of human cancers and is generally associated with poor clinical prognosis [8]. Therefore, it is not surprising that STAT3 signaling pathway has long been recognized as a potential therapeutic target for cancer therapy owing to their roles in tumor formation, metastasis and drug resistance [9–12]. Moreover, accumulating evidence reveals that STAT3 hyperactivation can mediate tumor-induced immunosuppression at many levels [13, 14]. Given the similarities between tumorigenesis and STAT3-dependent immunity, new therapeutic strategies that target STAT3 signaling pathway may open up new avenues for long-lasting and multilayered tumor control. This review outlines the role of the STAT3 pathway in tumor immunity, summarizes the recent progress in STAT3-centered anti-cancer approaches, and highlights future directions for the clinical immunotherapy. THE STAT3 SIGNALING PATHWAY STAT3 is a protein consisting of 770 amino acids and characterized by the presence of 6 functionally conserved domains, including the amino-terminal domain (NH2), the coiled-coil domain (CCD), the DNA-binding domain (DBD), the linker domain, the SRC homology 2 (SH2) domain, and the carboxyl-terminal transactivation domain (TAD) (Fig. 1a). Among them, SH2 is the most highly conserved STAT domain and plays a crucial role in signaling via binding to specific phosphotyrosine motifs [15]. In an unstimulated cell, STAT3 is tightly regulated by negative modulators to maintain an inactive state in the cytoplasm. These modulators include members of the protein inhibitor of activated STAT (PIAS), suppressor of cytokine signaling (SOCS) families, protein tyrosine phosphatases (SHP1, SHP2, PTPN1, PTPN2 PTPRD, PTPRT and DUSP22), and ubiquitin enzymes [8]. In response to stimuli, STAT3 becomes activated mainly by direct phosphorylation at tyrosine (705) and serine (727) residues induced by its upstream ligands including Janus kinases (JAKs), tyrosine kinases, cytokines and several non-receptor tyrosine kinases such as SRC and ABL; the phosphorylation induces dimerization of STAT3 proteins followed by nuclear translocation, DNA binding, and eventually execution of their nuclear functions [15]. Fig. 1The domain structure and signaling pathway of STAT3. a Schematic domain structure of STAT3. STAT3 is characterized by the presence of six different functional domains, including an amino-terminal domain (NTD) for cooperative binding of STAT proteins to multiple consensus DNA sites, a coiled-coil domain (CCD) for recruitment of STAT3 to the receptor as well as subsequent phosphorylation, dimerization and nuclear translocation, a DNA-binding domain (DBD) for recognizing and binding to a specific consensus DNA sequence, a linker domain for connecting the DBD with the SRC homology 2 (SH2) domain, a SH2 domain for recruitment and activation as well as dimerization of the STAT3 molecule by interacting with phosphorylated tyrosine residues in the opposing subunit, and a carboxyl-terminal transactivation domain (TAD). b STAT3 signaling pathway. STAT3 is activated by upstream growth factor kinases and cytokine receptors. Non-receptor tyrosine kinases such as SRC and ABL can also lead to constitutive activation of STAT3. Phosphorylated STAT3 dimerizes and translocates to nucleus, which causes the transcription of target genes including immunosuppression, angiogenesis, metastasis, proliferation and survival. The signaling pathway can be inhibited by SOCS proteins, PIAS proteins, and protein tyrosine phosphatases (PTPases), etc. c Interplay between noncoding RNAs and STAT3 signaling pathway. On the one hand, miRNAs and lncRNAs can regulate STAT3 activation through not only directly targeting STAT3, but also targeting the components of the STAT3 signaling pathway, such as IL-6, JAK2, SOCS1 and PIAS3; CircRNAs usually regulate STAT3 by acting as sponges for miRNAs. On the other hand, STAT3 is able to regulate miRNAs and lncRNAs expression in many ways. Beyond phosphorylation, other posttranslational modifications (i.e. acetylation, methylation, and sumoylation) can also regulate STAT3 transcriptional activity through altering STAT3 phosphorylation, and thus add another layer of complexity for STAT3 hyperphosphorylation in cancers (Fig. 1b). For instance, acetylation at several lysine residues within both the NH2 and SH2 domains, primarily mediated by the CBP/p300 acetyltransferase, can enhance STAT3 transactivating potential, which is associated with increased dimer stabilization, tyrosine 705 phosphorylation, nuclear translocation, and localized histone hyperacetylation of target promoters [16]. In contrast, deacetylation by several deacetylases, such as HADC1-3, SIRT1 and Loxl3, inhibits transcription of STAT3 targets [17–19]. The dynamic balance of acetylation and deacetylation plays a role in STAT3 activation and is involved in various cellular events. Similarly, methylation and sumoylation are also emerging as important regulatory mechanisms for STAT3 activity. SMYD2-dependent methylation of STAT3 contributes to the hyperphosphorylation of STAT3, whereas EZH2- and SET9-dependent dimethylation of STAT3 inhibits the activity of DNA-bound STAT3 dimers [20–22]. Sumoylation at the lysine 451 of STAT3 by SUMO2/3 can promote its interaction to the nuclear phosphatase TC45, thereby restraining phosphorylated STAT3 in the nucleus, while de-sumoylation by SENP3 leads to the hyperphosphorylation of STAT3 [23]. However, androgen receptor degradation enhancer ASC-J9 can inhibit the STAT3 phosphorylation via inducing the sumoylation of STAT3 at lysine 679 [24]. Additionally, increasing evidence suggests that noncoding RNAs (ncRNAs) can directly or indirectly modulate STAT3 activity (Fig. 1c). As the most extensively studied ncRNAs, numerous microRNAs (miRNAs) have been shown to

Read the complete text